Naim Hussein Y
a Life Sciences and Vaccines Consultant; Bern, Switzerland.
Hum Vaccin Immunother. 2015;11(1):21-6. doi: 10.4161/hv.34298. Epub 2014 Nov 1.
Measles was an inevitable infection during the human development with substantial degree of morbidity and mortality. The severity of measles virus (MV) infection was largely contained by the development of a live attenuated vaccine that was introduced into the vaccination programs. However, all efforts to eradicate the disease failed and continued to annually result in significant deaths. The development of molecular biology techniques allowed the rescue of MV from cDNA that enabled important insights into a variety of aspects of the biology of the virus and its pathogenesis. Subsequently these technologies facilitated the development of novel vaccine candidates that induce immunity against measles and other pathogens. Based on the promising prospective, the use of MV as a recombinant vaccine and a therapeutic vector is addressed.
麻疹是人类发展过程中一种不可避免的感染性疾病,具有较高的发病率和死亡率。减毒活疫苗的研发并引入疫苗接种计划,在很大程度上控制了麻疹病毒(MV)感染的严重程度。然而,所有根除该疾病的努力均告失败,每年仍导致大量死亡。分子生物学技术的发展使得从互补DNA(cDNA)中拯救出MV成为可能,这为深入了解该病毒生物学的各个方面及其发病机制提供了重要见解。随后,这些技术推动了新型候选疫苗的研发,这些疫苗可诱导针对麻疹和其他病原体的免疫力。基于这一前景广阔的预期,本文探讨了将MV用作重组疫苗和治疗载体的情况。